PRC200-SS is an experimental drug of the
triple reuptake inhibitor class that was investigated by the
Mayo Clinic.
Preclinical
In drug development, preclinical development, also termed preclinical studies or nonclinical studies, is a stage of research that begins before clinical trials (testing in humans) and during which important feasibility, iterative testing and drug ...
toxicology studies of PRC200-SS in
cynomolgus monkeys showed dose proportional kidney toxicity,
precluding any further
drug development
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for re ...
.
References
{{Monoamine reuptake inhibitors
Serotonin–norepinephrine–dopamine reuptake inhibitors
2-Naphthyl compounds
Amines
Secondary alcohols
Abandoned drugs